Sorafenib is an oral multi-kinase small molecule inhibitor that targets several serine/threonine and tyrosine kinases involved in tumor proliferation and angiogenesis, including Raf, VEGFR-2, VEGFR-3, and PDGFR-B. This evidence concerns the gene PDGFRB and neoplasm.